Fed Governor Adriana Kugler to resign
CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company focused on immunotherapy treatments with a market capitalization of $2.3 billion, has announced a registered direct offering aimed at raising approximately $75 million in gross proceeds. According to InvestingPro data, the company has been quickly burning through cash, making this financing crucial for its operations. The deal involves the sale of common stock to a single institutional investor, along with warrants for additional stock purchases. If exercised in full, these warrants could bring in an extra $90 million.
The offering is contingent on standard closing conditions and is being made under ImmunityBio's existing shelf registration statement. While the company maintains a healthy current ratio of 3.36, indicating strong short-term liquidity, further details will be available in a final prospectus supplement to be filed with the Securities and Exchange Commission (SEC).
ImmunityBio's work includes the development of therapies and vaccines to enhance the immune system's response against cancer and infectious diseases. Their product ANKTIVA, which has received FDA Breakthrough Therapy designation, is an immunotherapy for bladder cancer that activates various immune cells for a sustained response.
The company is also working on potential cancer vaccines and treatments that could reduce or eliminate the need for high-dose chemotherapy. These efforts are part of ImmunityBio's broader strategy to offer more effective and accessible treatments for oncology and infectious diseases.
The press release also includes forward-looking statements, cautioning that the proposed offering's completion and the anticipated use of proceeds are subject to risks and uncertainties. These include regulatory processes, clinical trial outcomes, and the company's ability to finance ongoing trials and commercialize its products.
This financing move comes as ImmunityBio continues to advance its clinical programs and strives to meet its operational and development goals. With analysts projecting sales growth and a beta of -0.13 indicating low correlation with market movements, the company presents a unique investment profile. For comprehensive analysis and additional insights, InvestingPro subscribers can access 8 more exclusive ProTips and detailed financial metrics about ImmunityBio's growth potential.
In other recent news, ImmunityBio, Inc. reported impressive fourth-quarter results, surpassing analyst expectations. The company posted a Q4 adjusted loss of $0.09 per share, beating the anticipated loss of $0.17 per share. Revenue for the quarter surged to $7.2 million, significantly above the previous year's zero revenue and the consensus forecast of $6.16 million. This growth was primarily driven by sales of the ANKTIVA therapy, approved by the FDA in April 2024. Additionally, ImmunityBio appointed Deloitte & Touche LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2025, following the dismissal of Ernst & Young LLP.
The company also announced an Expanded Access Program (EAP) to distribute recombinant BCG (rBCG), addressing a significant shortage in the U.S. market for non-muscle invasive bladder cancer treatment. H.C. Wainwright maintained a Buy rating for ImmunityBio with a price target of $8.00, reflecting confidence in the company's strategy. The firm also highlighted potential risks, including clinical, regulatory, and financial challenges. Despite these risks, ImmunityBio's recent developments, including the EAP and ANKTIVA's growing adoption, mark a positive trajectory for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.